BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

Session 4 – Exit Strategies for Early Stage New Drug Companies

Session 4 – Exit Strategies for Early Stage New Drug Companies

Date:27 July (Wednesday) 14:00 – 15:30 (GMT+8)
Venue:701EF, TaiNEX2, Taipei + Online event platform

Drug development is an expensive business, with the average cost of bringing a new drug to market nearly US$1 billion—according to research from the London School of Economics—with a typical asset changing hands many times as it moves up the value chain. VC firms have typically been more interested in funding drugs already in clinical development, but more and more are adjusting their risk-reward profile and discovering opportunity in early-stage drugs and nimble startups. Asian innovation and its thousands of startups in this industry space have flown under the radar for too long but at last are coming to the attention of the international investment community. Join us in this session hosted by PricewaterhouseCoopers (PwC) as our panel of finance and investment experts dive deep into the world of cross-border investments, with an Asian focus.